USNA Usana Health Sciences Inc

  1. Stocks
  2. Consumer Defensive
  3. NYSE: USNA

Price (delayed)

$44.13

Market cap

$849.08M

P/E Ratio

13.33

Dividend/share

N/A

EPS

$3.31

Enterprise value

$519.45M

USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25 ...

Highlights
The quick ratio has grown by 38% YoY
The price to earnings (P/E) is 27% lower than the last 4 quarters average of 18.2 and 16% lower than the 5-year quarterly average of 15.8
The EPS has contracted by 8% YoY but it has grown by 7% from the previous quarter
USNA's net income is down by 8% year-on-year but it is up by 7% since the previous quarter
USNA's revenue is down by 8% year-on-year
The gross profit has declined by 8% year-on-year
Sector: Consumer Defensive
Industry: Household & Personal Products
Website: http://www.usana.com
Peers: NATR NUS PRPH MTEX

Key stats

What are the main financial stats of USNA
Market
Shares outstanding
19.24M
Market cap
$849.08M
Enterprise value
$519.45M
Valuations
Price to earnings (P/E)
13.33
Price to book (P/B)
1.7
Price to sales (P/S)
0.92
EV/EBIT
5.06
EV/EBITDA
4.22
EV/Sales
0.56
Earnings
Revenue
$921.01M
EBIT
$102.72M
EBITDA
$123.11M
Free cash flow
$56.16M
Per share
EPS
$3.31
Free cash flow per share
$2.92
Book value per share
$25.99
Revenue per share
$47.84
TBVPS
$30.43
Balance sheet
Total assets
$632.76M
Total liabilities
$135.56M
Debt
$786,000
Equity
$497.2M
Working capital
$298.9M
Liquidity
Debt to equity
0
Current ratio
3.52
Quick ratio
2.78
Net debt/EBITDA
-2.68
Margins
EBITDA margin
13.4%
Gross margin
80.8%
Net margin
6.9%
Operating margin
10.1%
Efficiency
Return on assets
10.4%
Return on equity
13.5%
Return on invested capital
75.4%
Return on capital employed
20%
Return on sales
11.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
1.52%
1 week
0.36%
1 month
-8.33%
1 year
-31.03%
YTD
-17.67%
QTD
-9.01%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$921.01M
Gross profit
$744.32M
Operating income
$93.07M
Net income
$63.79M
Gross margin
80.8%
Net margin
6.9%
The operating income has declined by 14% year-on-year
USNA's revenue is down by 8% year-on-year
USNA's net income is down by 8% year-on-year but it is up by 7% since the previous quarter
The gross profit has declined by 8% year-on-year

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
USNA P/E details
P/E
13.33
P/B
1.7
P/S
0.92
EV/EBIT
5.06
EV/EBITDA
4.22
EV/Sales
0.56
The price to earnings (P/E) is 27% lower than the last 4 quarters average of 18.2 and 16% lower than the 5-year quarterly average of 15.8
The EPS has contracted by 8% YoY but it has grown by 7% from the previous quarter
USNA's P/B is 55% below its 5-year quarterly average of 3.8 and 29% below its last 4 quarters average of 2.4
The company's equity rose by 14% YoY and by 6% QoQ
USNA's price to sales (P/S) is 34% less than its 5-year quarterly average of 1.4 and 23% less than its last 4 quarters average of 1.2
USNA's revenue is down by 8% year-on-year

Efficiency

How efficient is Usana Health Sciences business performance
The company's return on invested capital fell by 21% YoY
The ROE has contracted by 16% YoY but it has grown by 3.1% from the previous quarter
Usana Health Sciences's ROA has decreased by 10% YoY but it has increased by 5% from the previous quarter
The ROS has grown by 6% from the previous quarter and by 2.8% YoY

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The quick ratio has grown by 38% YoY
The current ratio has increased by 32% YoY
USNA's debt is 100% less than its equity
The company's equity rose by 14% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.